An efficient ELISA protocol for measurement of SARS-CoV-2 spike-specific IgG in human plasma and serum samples.

Publication date: Jun 01, 2024

Here, we describe a protocol for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike-specific immunoglobulin G (IgG) by enzyme-linked immunosorbent assay (ELISA). The protocol was developed with a keen focus on optimizing several key parameters, including antigen coating concentration, antibody and sample dilutions, and assay development time. The final protocol features the following characteristics:•The capability to detect SARS-CoV-2 spike-specific IgG in both plasma and serum samples. •A streamlined procedure that requires only 1 hour and 20 minutes of hands-on time. •Reliable assay performance, with a remarkable sensitivity of 98. 1 % and specificity of 99. 5 %.

Open Access PDF

Concepts Keywords
Elisa ELISA
Hour IgG
Immunoglobulin SARS-CoV-2 spike
Plasma
Reliable

Semantics

Type Source Name
disease VO efficient
disease VO protocol
disease VO Severe acute respiratory syndrome coronavirus 2
disease IDO assay
disease VO time
drug DRUGBANK Coenzyme M
disease MESH AIDS
drug DRUGBANK Sodium bicarbonate
drug DRUGBANK Phosphate ion
drug DRUGBANK Human Serum Albumin
drug DRUGBANK Immune Globulin Human
disease IDO production
disease MESH COVID 19 pandemic
disease IDO immunodeficiency
disease MESH HIV infection
pathway REACTOME HIV Infection
disease VO efficiency
disease MESH immobilization
drug DRUGBANK Methionine
disease VO storage
disease IDO process
disease IDO quality
disease MESH Pneumonia
disease VO Env

Original Article

(Visited 2 times, 1 visits today)